Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05572593 · ClinicalTrials.gov registry record · NA
Utility of Pharmacogenomic Testing in Patients With Gastrointestinal Disorders
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
NCT05572593: Completed NA study, sponsored by Mayo Clinic.
NCT05572593 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 97 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05572593, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
Study Summary
Researchers are trying to learn more about how individuals break down and process specific medications based on their genes. Pharmacogenomics (PGx) is a new, specialized field within individualized medicine. PGx is the study of how genes may affect the body's response to, and interaction with, some prescription medications. Genes carry information that determines things such as eye color and blood type. Genes can also influence how individuals process and respond to medications. Depending on genetic make-up, some medications may work faster or slower or produce fewer side effects.
Interventions
- GENETIC Pharmacogenomics (PGx) genetic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2021-09-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05572593
The ClinicalTrials.gov registry entry for NCT05572593 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenomics (PGx) genetic testing is the first listed.
NCT05572593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05572593 about?
NCT05572593 is a clinical study titled "Utility of Pharmacogenomic Testing in Patients With Gastrointestinal Disorders". Researchers are trying to learn more about how individuals break down and process specific medications based on their genes. Pharmacogenomics (PGx) is a new, specialized field within individualized medicine. PGx is the study of how genes may affect the body's response to, and interaction with, some ...
What is the current status of trial NCT05572593?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2018-02-08. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT05572593?
The interventions under investigation include: Pharmacogenomics (PGx) genetic testing (GENETIC).
Who is sponsoring clinical trial NCT05572593?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.